Sedana Medical AB (publ), Second Quarter Report 2021
European approval of SedacondaSecond quarter 2021 · Net sales totalled MSEK 40 (41), equivalent to a decrease of 2 percent compared to the second quarter of 2020. At constant exchange rates, sales increased by 3%. In May and June, we saw a slowdown in the third wave of the pandemic in Europe, while it is increasing in Latin America and other regions in our distributor markets. · Gross profit was MSEK 26 (26), equivalent to a margin of 66% (64%). The improved margin is mainly an effect of lower transport costs during the quarter as a larger share of freight was carried by sea rather